The hospital's post lands on a tension we see play out across every regulated industry right now. The hospital is not asking how to build a model. They are asking how to prove a model keeps working, shift after shift, when the ground truth is a patient outcome and the vendor is a black box. That is a different discipline entirely. The platform comparison between ClearML and OpenShift AI matters, but only as a starting point. The real weight sits downstream, in the monitoring layer, and the fact that neither tool answers the question natively is not a gap. It is the thesis.
We would tell this team to stop looking for a single platform that does everything and start treating monitoring as the contract every model must sign before it reaches a clinical workflow. The self-service model they describe is the right instinct. Central IT should not be the choke point for twelve teams, but guardrails are not bureaucracy. They are the difference between a model that is deployed and a model that is defensible. Their instinct to run Evidently AI alongside the platform, compute metrics in a pipeline, and push to Grafana is pragmatic. It separates the compute from the evidence. That separation is the only way to handle the vendor models anyway, since a sidecar is not an option when the serving runtime lives behind someone else's firewall. The input/output data feed they are writing into procurement contracts is the single most important decision in this entire post. If the data is not there, the monitoring is not possible. The legal obligation to monitor is meaningless without the raw material to monitor.
What stands out is the maturity of their bias requirement. They are not asking for statistical parity. They are asking for sensitivity, specificity, and calibration per subgroup, because they know a model that misses a fracture in a woman at a higher rate than a man is not a fairness metric. It is a patient safety issue. That level of specificity should be the floor for any hospital deploying predictive models, and it is striking how rare that clarity is. The Monitor Cypress Tests with Grafana: Persistent Observability for Your Data approach of converting events into time-series metrics is exactly the pattern they need to replicate, just with clinical inferences instead of test steps. The same logic applies to the Claude Now Watermarks Everything It Makes reality of AI generation, where provenance and audit trails are becoming non-negotiable. If you cannot trace what the model saw and predicted, you cannot defend the action taken on it.
The open question we would push back on is the alerting ownership model. They say monitoring nobody responds to is worthless, and they are right. But who gets paged when a vendor model drifts at 2 a.m.? The platform team cannot own clinical risk. The clinical team cannot own infrastructure. That ownership gap is where most MLOps programs in hospitals quietly die. We would advise them to name a responsible clinician for each model before the first dashboard goes live. The [I have a mid-sized GPU cluster and was thinking about giving free compute [D]](/post/i-have-a-mid-sized-gpu-cluster-and-was-thinking-about-giving-cmt3m5cx30md5mi9ze14rws42) post may be about a different scale, but the principle holds: free or self-service compute without a defined operational owner is just a future incident with a timestamp. The platform is the easy part. The accountability is the product.